Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther 2014 Aug;28(4):313-22
Date
05/21/2014Pubmed ID
24842561DOI
10.1007/s10557-014-6530-0Scopus ID
2-s2.0-84927170630 (requires institutional sign-in at Scopus site) 25 CitationsAbstract
PURPOSE: Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartan medoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome.
METHODS: Male SHROB were treated with vehicle or AZL-M orally for 56 days. Vehicle treated normotensive Wistar-Kyoto (WKY) rats served as controls. The effects of AZL-M on kidney injury, vascular endothelial and heart functions, lipid profile, and glucose tolerance were assessed.
RESULTS: AZL-M demonstrated anti-hypertensive effects along with markedly improved vascular endothelial function in SHROB. In these rats, AZL-M demonstrates strong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB.
CONCLUSION: Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.
Author List
Hye Khan MA, Neckář J, Cummens B, Wahl GM, Imig JDMESH terms used to index this publication - Major topics in bold
AnimalsAntihypertensive Agents
Benzimidazoles
Blood Glucose
Body Weight
Cholesterol
Disease Models, Animal
Heart
Hypertension
Hypertrophy, Left Ventricular
In Vitro Techniques
Insulin
Kidney
Male
Mesenteric Arteries
Myocardium
Obesity
Oxadiazoles
Protective Agents
Rats, Inbred WKY
Triglycerides
Vasodilation
